| 07/03/2026 09:30 |
Receives Notice of Allowance in the U.S. for Patent Application Relating to the Therapeutic Use of PPMX-T003 for Polycythemia |
| 07/01/2026 15:30 |
Notice Regarding the Results of a Clinical Study in Patients Who Participated in the Phase I Clinical Trial of PPMX-T003 for Polycythemia Vera |
| 06/23/2026 11:00 |
Perseus Proteomics Signs Memorandum of Understanding with EirGenix to Explore Collaboration in Antibody Drugs |
| 06/15/2026 15:30 |
Notice Regarding Patent Grant Based on Joint Research with Nagoya University |
| 05/20/2026 15:30 |
Notice Concerning Executive Appointments |
| 05/18/2026 15:30 |
Presentation Material for FY2026/3 Business Results |
| 05/14/2026 15:30 |
Notice on Recording of Non-operating Income, Non-operating Expenses, and Extraordinary Losses |
| 05/14/2026 15:30 |
Non-consolidated Summary of Financial Results for the Fiscal Year Ended March 31, 2026 |
| 04/01/2026 15:30 |
FY2026 Medical R&D Program grant awarded for development of PPMX-T003 Aggressive NK-Cell leukemia |
| 03/31/2026 15:30 |
Notice Regarding Full-Year Earnings Forecast for the FY2026/3 |
| 03/17/2026 15:30 |
Perseus Proteomics Inc. Announces Notice of Allowance in the U.S. for Patent Relating to Antibody-Based Radiopharmaceutical Formulation Technology |
| 02/25/2026 16:00 |
Announcement of a Presentation at an International Symposium Regarding PPMX-T003 |
| 02/13/2026 16:00 |
Non-consolidated Summary of Financial Results for the Third Quarter of the Fiscal Year Ending March 31, 2026 |
| 02/13/2026 16:00 |
Notice on Recording of Non-operating Income, Non-operating Expenses, and Extraordinary Losses |
| 12/04/2025 15:30 |
Announcement of Presentation at The 4th Annual Meeting of The Japanese Antibody Society |
| 12/01/2025 15:30 |
Notice of Joint Research Agreement with Eurus Therapeutics Inc. for the Utilization of PPMX Antibody Library |
| 11/18/2025 16:00 |
Presentation Material for FY2026/3 First Half Business Results |
| 11/14/2025 15:30 |
Notice of Extension of Investigator-Initiated Phase I/II Clinical Trial Period for PPMX-T003 in Aggressive NK-Cell Leukemia (ANKL) |
| 11/14/2025 15:30 |
Notice on Recording of Non-operating Income, Non-operating Expenses, and Extraordinary Losses |
| 11/14/2025 15:30 |
Non-consolidated Summary of Financial Results for the Second Quarter of the Fiscal Year Ending March 31, 2026 |
| 11/05/2025 15:30 |
Notice Regarding Execution of Joint Research Agreement between PPMX and ASKA Pharmaceutical for Creation of Novel Antibody Drugs |
| 10/08/2025 15:30 |
Announcement of New Antibody and Reagent Product Launch |
| 09/18/2025 15:30 |
Announcement of Acceptance for Three Poster Presentations at the 4th Annual Meeting of the Japan Antibody Society |
| 08/14/2025 15:30 |
Non-consolidated Summary of Financial Results for the First Quarter of the Fiscal Year Ending March 31, 2026 |
| 08/14/2025 15:30 |
Business Results Summary for Q1 FY2026/03 |
| 08/14/2025 15:30 |
Notice on Recording of Non-operating Income, Non-operating Expenses, and Extraordinary Losses |
| 07/08/2025 15:30 |
Notice of Acceptance for Presentation at the 84th Annual Meeting of the Japanese Cancer Association |
